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ABSTRACT 
OBJECTIVE:  The objective of the systematic review is to determine whether or not chronic use 
of Bacopa monnieri is an effective treatment to improve memory performance in healthy and 
aging adults.  
STUDY DESIGN: Review of three English language primary studies published in 2006, 2008 
and 2008. 
DATA SOURCES: Randomized, double-blind, placebo-controlled trials comparing chronic use 
of Bacopa monnieri extract to placebo were found using Ovid MEDLINE, PubMed and 
Cochrane databases.  
OUTCOMES MEASURED:  Ability to recall newly learned information evaluated using the 
Cognitive Drug Research (CDR) cognitive assessment system, the Rey Auditory Verbal 
Learning Test (AVLT) and the Wechsler Memory Scale.  
RESULTS: All three RCT’s included in this review found significant improvement versus 
placebo in the realm of recalling newly learned information, specifically in spatial working 
memory, paired associated learning and delayed word recall memory tests.  
CONCLUSIONS: The results of the RCT’s reviewed demonstrate that chronic use of B monnieri 
extract has the potential to significantly improve cognitive function, namely the ability to recall 
newly learned information, in healthy as well as the elderly with age-related cognitive 
impairment. 
KEY WORDS:  Bacopa monnieri, Brahmi, cognitive, memory 
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INTRODUCTION 
 Memory, or the ability to recall information, is a common subject of complaint in 
healthcare as evidenced by the ADHD patient who cannot remember what he or she just read or 
by the aging patient who complains of an increasing inability to think of the right word to 
describe something. Even in the perfectly healthy individual memory has its limit. The desire to 
improve one’s memory is near universal, and a recent study at the University of Sterling found 
that people with better working memory tend to be happier and more successful.1  While 
memory is a multifactorial and not fully understood process, the weakening of the memory can 
be disabling and costly to patients. Conversely, the improvement of memory can lead to more 
effective living.  
 As many as one-third of adults will experience mild cognitive decline as they age4, and 
with an aging baby-boomer demographic beginning to enter their golden years, a desire for 
treatment and improvement in memory may increase in demand. While drugs such as Aricept 
and Namenda are being effectively used for Alzheimer’s related cognitive decline, no 
pharmaceutical drugs or supplements are FDA approved to improve normal or age-related 
memory decline. Concurrently, there is a trend towards health consumers turning to 
complementary and alterative medicine (CAM) in the United States, with approximately $34 
billion spend on it in 20077. A recent report revealed Americans spent $107 million dollars on 
gingko biloba in hopes to improving memory.2 As patients in a primary care setting increasingly 
inquire about supplements and herbs such as ginkgo--and indeed may be taking them without the 
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providers’ knowledge-- it becomes important to know the evidence in order to educate patients in 
making informed decisions with their health.  
 Traditionally conservative methods such as low fat diets, regular exercise, adequate 
intake of fish, tight glucose control and adequate sleep of all been posited to stave off or improve 
memory decline.4  While the exact workings of memory and its decline are unknown, researchers 
have pointed to declining levels of neurotransmitters such as acetylcholine, serotonin and DHEA, 
a decrease in neurons and frequency of nerve impulses, oxidative damage to neurons (especially 
in the hippocampus), chronic inflammation and decreased blood flow to the brain, among others 
as responsible mechanisms.4 Many supplements ranging from B-vitamins to coffee to “smart 
drugs” like piracetam are marketed to improve cognitive function and enhance memory. As 
interest and research grows in this field, efforts must be made to evaluate the evidence to support 
their use. To illustrate the importance of evidence behind these therapies, a recent, federally 
funded study to evaluate gingko biloba in preventing age related cognitive decline was published 
in JAMA in 2009 and showed no difference versus placebo.3 
 Bacopa monnieiri  (Brahmi) is another herb—a leaf extract of water hyssop, a popular 
aquarium plant--has garnered recent attention for its potential in improving memory.  It is being 
sold today in health food stores such as Whole Foods an GNC. Traditionally it has been used as 
far back as the 6th century in Ayurvedic medicine for enhancing memory, analgesia and treating 
epilepsy.5  Today it is being used in alternative medicine and supplement for cognition, memory, 
anxiety, IBS and epilepsy. The exact mechanism of action is unknown, but it is thought that 
saponins from B monnieri are responsible for its positive effects, hypothetically by upregulation 
of cholinergic regulation, GABA modulation with anxiolytic effects, antioxidant effects in the 
prefrontal cortex, striatum and hippocampus (as evidenced in chronic use in mice models), 
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altered protein synthesis in the brain, 5-HT agonism and modulation of brain stress hormone. 
8,9,10  Early trials have not shown any significant benefit from B monnieiri use in the acute setting, 
but small and preliminary studies have shown some promise of benefit in the arena of memory 
with chronic use (90 days) of B monnieri.  
OBJECTIVE 
 The goal of this review is to determine if chronic use (of at least 3 months) of a 
standardized extract of B monnieri is an effective treatment to improve memory performance in 
healthy and aging adults.  
 
METHODS 
 A search to locate RTC’s that evaluated extract of B monnieiri on memory performance 
in adults was performed. The different interventions used were 300mg standardized extract/day 
taken for 12 weeks; 150mg of specialized extract for twice a day for 90 days; and 125mg of 
standardized extract taken twice a day for 12 weeks followed by four weeks of placebo. The 
common denominator of these studies is administration of at least 250mg per day for at least 12 
weeks (84 days). All of these interventions were compared versus placebo. Outcomes included 
working memory, word recall, spatial memory, anxiety and visual information processing. The 
studies included in this review were all randomized, double-blind placebo controlled studies.  
 Key words used for the search were “Brahmi” (the Indian name for B monnieiri), “B 
monnieiri”, “cognitive” and “memory”. All three studies were published and written in the 
English language. The Cochrane Database of Systematic Reviews, PubMed and Ovid 
MEDLINE—“2000 to present” were used to locate the studies published in 2006, 2008 and 2008 
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respectively. Criteria for selection were those published in 2000 or later, included human beings 
and were in the English language, dealt with POEMS and were RCT’s not previously used for 
SRs or MAs.  The researchers of the studies were from the Brain Sciences Institute from 
Swinburne University, KG Medical University researchers in India, and the National College of 
Natural Medicine in conjunction with OHSU in Portland, Oregon.  
 
OUTCOMES MEASURED 
 The outcomes evaluated in the respective studies were POEMS such as the ability to 
recall new information, change in anxiety level, attention, working memory, spacial working 
memory and the ability to recall information after delay or with distraction. To evaluate these 
POEMS, the Wechsler Memory Scale, Cognitive Drug Research cognitive assessment system 
(CDR) and Rey Auditory-Verbal Learning Test (AVLT) were used. All three of the studies used 
very similar interventions of at least 250mg of a standardized or “specialized” B monnieiri 
extract that included at least 50% concentration of bacosides A and B versus placebo. They were 
all conducted over chronic courses defined as at least 12 weeks. Two of the studies used healthy 
adult populations while the other study used a population of adults with complaints of insidious 
age-related cognitive impairments. The major characteristics of the studies under review are 
organized in Table 1. 
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Table of demographics of included studies: Table 1 
CHARACTERISTICS OF STUDIES INCLUDED IN THE SYSTEMATIC REVIEW OF 
THE EFFICACY OF BACOPA MONNIERI VERSUS PLACEBO IN IMPROVING 
MEMORY PERFORMANCE 
Study Type #Pts Age/ 
Yrs 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Calabrese, 
2008 (1) 
Double-
blind, 
placebo 
controlled 
RCT 
54 65+ Living 
independently, 
without signs 
of dementia 
No meds other 
than ASA, 
NSAIDs, 
vitamins, 
stable doses of 
thyroid med, 
HRT, anti-
HTN or 
cholesterol 
drugs 
6 Standardized 
B. monnieri 
extract of 
300 mg/day 
taken orally 
for 12 weeks 
Stough, 
2008 (2) 
Double-
blind, 
placebo 
controlled 
RCT 
107 18- 
60 
Healthy Hx of 
dementia, 
psychiatric or 
neurological 
disorders 
endocrine 
disorder, 
chronic illness 
or infection, 
pregnant or 
lactating, 
Taking anti-
coagulators, 
ACE 
inhibitors, anti-
Parkinson’s or 
any other 
cognition 
enhancing 
drug, cigarette 
smoking.  
35 Specialized 
extract of B. 
monnieri 
300mg/day 
taken orally 
or 90 days 
Raghav, 
2006 (3) 
Double-
blind, 
placebo 
controlled 
RCT 
40 55+ Complaints of 
insidious-
onset memory 
impairment. 
<6 on 
Wechsler 
Memory Scale 
Evidence of 
dementia or 
psychiatric 
disorder. 
> 24 on 
MMSE 
5 Standardized 
B. monnieri 
extract 
125mg BID 
for 12 weeks 
followed by 
4 weeks of 
placebo 
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RESULTS   
 Table 2 displays a summary of results from a study conducted by Calabrese et al. in 
2008. For the purpose of this analysis, results from the AVLT, or the Rey Auditory-Visual 
Learning Test, were chosen from the battery of measurements only if they directly related to 
memory. The AVLT measures short-term auditory-verbal memory among other facets of the 
memory such retention, retrieval accuracy and the like.8 The Blessed Orientation-Memory-
Concentration (BOMC) and Wide Range Achievement Test (WRAT) were administered at 
baseline to participants and along with gender were analyzed using ANCOVA and ANOVA to 
determine if covariate were effecting significance. F values were all < 1 signifying that 
covariates did not differ between groups or gender.8 The ability of the bacopa group to recall 
words after delay had a significant increase (p 0.03) whereas placebo did not. The control group 
recall scores did not change significantly over 12 weeks, while the experimental arm scores 
increased by 1 word over 12 weeks. Significance was not seen until the 12th week interval 
testing.8  
  
Table 2. Comparing AVLT Delayed Recall Scores Over Time in B monnieiri Versus Placebo8 
Calabrese et al., 2008 
Means for Cognitive Measures at Baseline, 6 weeks and 12 weeks in using AVLT Delayed 
Recall (# of words)  
Variables Group Baseline 
M (SD) 
+6 weeks 
M (SD) 
+12 weeks 
M (SD) 
F df p η 
Placebo 6.8 (3.6) 6.6 (3.9) 6.9 (4.2) <1    AVLT 
Delayed Recall 
    (# of words) Bacopa 6.4 (3.1) 6.6 (3.6) 7.6 (3.9) 5.4 1,21 0.03 0.20 
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 The results from a 2008 study conducted by Stough et al. are presented in Table 3 and 
Table 4. The main evaluation in this experiment used the CDR computerized assessment test. 
The CDR assesses speed of attention, speed of memory, accuracy of attention, secondary and 
working memory via a variety of tests9. For the purpose of this analysis, only measures 
pertaining to secondary and working memory were examined. ANOVA conduction revealed a 
significance within the class of “Working Memory” tests F(1,53) = 4.70, p = 0.035 (Table 4) and 
specifically within in this class, “Spatial Working Memory” improved significantly F(1,54) = 
3.98, p = 0.051 (Table 3).9  It is important to note that in the class of “Secondary Memory” there 
was no significant difference between groups. Note that secondary memory is also referred to as 
long-term memory in psychological parlance. In the specific tests of numeric-working memory, 
delayed-word recall, word-recognition recall and delayed-picture recall, no significant difference 
between placebo and the experimental arm was detected.  
 
Table 3. Effect of B monnieri treatment on the CDR measure of spatial working memory9 
C. Stough et al, 2008 study 
Measure Tx group N Mean SD Baseline Mean SD Post Tx 
Placebo 28 95.67 6.91 97.97 2.53 Spatial Working 
Memory (% 
Correct) Bacopa 33 91.40 9.99 96.84* 5.91 
Placebo 28 92.94 6.34 91.89 8.26 Numeric Working 
Memory (%) 
correct Bacopa 33 93.70 6.15 93.80 5.22 
Placebo 29 28.74 11.90 34.37 13.37 Delayed Word 
Recall (%) Bacopa 31 31.61 14.40 34.58 14.46 
Placebo 29 81.72 11.43 84.14 8.48 Word Recognition 
Recall (%) Bacopa 33 83.84 8.50 85.15 9.43 
Placebo 29 84.40 7.75 86.90 9.18 Delayed Picture 
Recognition (% 
correct) Bacopa 33 86.29 8.73 86.82 10.94 
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Table 4. Baseline and Post-treatment scores for the “working memory” CDR measure9 
C. Stough et al, 2008 study 
CDR factor Treatment M (baseline) SD (baseline) M (post-tx) SD (post-tx) 
Bacopa 185.11 13.16 190.64 * 9.39 Working 
Memory Placebo 188.71 9.50 189.85 9.08 
Bacopa 246.64 33.73 254.66 39.36 Secondary 
Memory Placebo 236.93 34.75 251.49 34.53 
 * p < 0.05 
 Table 5 shows the results from a 2006 study conducted by Raghav et al., a study that 
used participants who have age-related cognitive impairment in contrast to the other two studies 
in this review.  The Wechsler Memory Scale was used to evaluate memory function. Subtests of 
the WMS were used and are represented in Table 5. At 12 weeks, paired t-test analysis showed 
significant improvement in the Bacopa arm in the areas of mental control, logical memory, 
paired associate learning and total memory score (p < 0.01) as well as in digit forward (p < 
0.05).10 No significant differences were seen in digit backward testing and visual reproduction 
measures. Moreover, no memory loss nor loss of gains was seen from week 12 to week 16 in the 
Bacopa arm when placebo was used in both groups for the last four weeks. When improvement 
of > 21% is set to define what constitutes a considerable gain, 55% of the Bacopa subjects 
improved considerably as opposed to none in the placebo group.10 With this dichotomous 
determination made, NNT would be 2 patients.  
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Table 5. Comparison of Wechsler Memory Scale scores of B monnieri versus placebo groups at 
0, 4, 8, 12 and 16 weeks10 
Raghav et al, 2006  
Variables 0 week 4 week 8 week  12 week  16 week  
Mental Control  
Bacopa 7.4 +/- 0.9 7.8 +/- 0.7 8.2 +/- 0.9 8.6 +/- 0.6** 8.6 +/- 0.6 
Placebo 7.7 +/- 0.6 7.7 +/- 0.6 8.0 +/- 0.4 8.0 +/- 0.4 8.0 +/- 0.4  
‘t’  1.94 2.06 3.53  
Logical Memory 
Bacopa 4.3 +/- 1.1  5.9 +/- 1.2** 7.4 +/- 1.2** 8.7 +/- 2.1 ** 8.8+/- 2.1 
Placebo 4.8 +/- 1.1  5.5 +/- 1.3 6.4 +/- 1.8* 6.7 +/- 1.6 6.7 +/- 1.4 
‘t’  2.58 2.47 3.48  
Paired Associate Learning 
Bacopa 13.9 +/- 3.6 14.6 +/-3.3  16.8 +/-2.4 ** 18.1 +/- 2.3** 18.2 +/- 2.1 
Placebo 12.7 +/- 1.4 13.2 +/- 1.2 13.7 +/- 2.1* 14.5 +/ -1.8 14.5 +/ -1.7 
‘t’  1.26 1.9 2.48  
Digit Forward      
Bacopa 6.3+/- 0.5 6.8 +/- 0.7 6.6 +/- 0.7 7.0 +/- 0.7* 7.0+/- 0.4 
Placebo 6.8 +/- 0.7 6.7 +/- 0.7  6.8 +/- 0.6 6.8 +/- 0.7 6.8 +/- 0.6 
‘t’  1.4 0.55 0.96  
Digit Backward 
Bacopa 5.5+/- 0.3 5.2 +/- 0.4 5.2 +/- 0.5 5.2 +/- 0.4 5.9 +/- 0.8 
Placebo 5.7 +/- 0.7 5.7 +/- 0.8 5.6 +/- 0.6 5.7 +/- 0.6 5.7 +/- 0.6  
‘t’      
Visual Reproduction 
Bacopa 11.7 +/- 1.6 11.5 +/- 1.7 11.6 +/- 1.6 11.7 +/- 1.7 11.7 +/- 1.7 
Placebo 12.0 +/- 1.9 12.1 +/- 1.8 12.0 +/- 2.1 12.1 +/- 2.2 12.1 +/- 2.1  
‘t’      
Total Memory Score 
Bacopa 57.4+/- 4.4 60.8 +/- 4.7* 66.9 +/- 4.7** 70.2 +/- 4.8** 70.6 +/- 4.0 
Placebo 57.5 +/- 3.1 59.1 +/- 3.4 63.3 +/- 4.9 64. 6 +/- 4.8 64.4 +/- 4.9 
‘t’  2.87 10.7 4.98  
* p < 0.05  ** p< 0.01 
 
 As mentioned previously, one study did use subjects with insidious age-related cognitive 
impairment (Raghav et al.) while the others used healthy participants. Exclusion criteria were 
similar and only one study reported compliance (Calabrese et al.), which was high with an 
average of 3.9 pills missed over 12 weeks with no significant difference between control and 
interventional arm.8,10 Adverse advents, although not under examination in this review, are still 
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worth mentioning as it might affect compliance, but in all three studies no significant difference 
between placebo and Bacopa intervention.8,9,10  
DISCUSSION 
  Each study showed some significant improvement in a facet of memory with the most 
impressive gains reported in the Raghav et al. study in which participants were suffering from 
age-related cognitive impairment with a Wechsler score < 6.10  It is not understood why gains 
would be made in one area of memory and not others, but what the statistics do bear out is that 
working or “short-term memory,” to put it simply, is significantly improved in the interventional 
group in all 3 studies. Certain subtests in the studies such “visual reproduction” (Raghav study) 
and “numeric working memory” (Stough study) show no difference between groups. Given the 
complexity of the human brain and memory, it is difficult to say why this would be. An obvious 
limitation of all of the studies in this review is small sample size that confers weak statistical 
power.  
 With respect to clinical use of this herb, the Natural Standard reports that palpitations, dry 
mouth, nausea and fatigue have been reported with use.5  Based on animal studies, caution 
should be used in patients taking drugs metabolized by the cytochrome P450 enzyme, in patients 
receiving treatment for thyroid disorders as it may increase levels and patients taking CCBs or 
sedatives to potentiation due to potential additive effects.5  
CONCLUSION 
 Yes, B monnieiri has the potential to be an effective treatment to improve memory 
performance in both the healthy and aging adults, including those suffering from age-related 
memory impairment. It is recommended that large scale, long duration studies are conducted to 
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confirm and strengthen the evidence for using this herb. Moreover, long-term studies might be 
explored for its potential to play a role in protecting or delaying age-related memory decline or 
delay Alzheimer’s disease onset and/or progression. It is interesting to note that cognitive gains 
made in the Raghav study that involved patients with insidious age-related cognitive impairment 
were maintained even after discontinuing the intervention. This is a promising clinical POEM 
that would benefit patients if larger studies bear out similar significant evidence in the future.  
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